A Phase 2a Study to Evaluate the Safety and Efficacy of Namilumab in Subjects With Moderate-to-severely Active Axial Spondyloarthritis
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Namilumab (Primary)
- Indications Ankylosing spondylitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NAMASTE
- Sponsors Izana Bioscience
- 16 Apr 2020 Status changed from active, no longer recruiting to completed.
- 20 Aug 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2019.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.